公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2008 | Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern | SHANG-GIN WU ; YIH-LEONG CHANG ; Hsu Y.-C.; Wu J.-Y.; CHIH-HSIN YANG ; CHONG-JEN YU ; Tsai M.-F.; JIN-YUAN SHIH ; PAN-CHYR YANG | Oncologist | 72 | 67 | |
2011 | Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations | SHANG-GIN WU ; CHIH-HSIN YANG ; CHONG-JEN YU ; JIH-HSIANG LEE ; Hsu Y.-C.; YIH-LEONG CHANG ; JIN-YUAN SHIH ; PAN-CHYR YANG | Lung Cancer | 41 | 35 | |
2021 | Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey | Garrido P.; Adjei A.A.; Bajpai J.; Banerjee S.; Berghoff A.S.; Choo S.P.; Felip E.; Furness A.J.S.; Garralda E.; Haanen J.; Letsch A.; Linardou H.; Peters S.; Sessa C.; Tabernero J.; Tsang J.; CHIH-HSIN YANG ; Garassino M.C. | ESMO Open | 16 | 14 | |
2011 | Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS) | Thongprasert S; Duffield E; Saijo N; Wu Y.-L; CHIH-HSIN YANG ; Chu D.-T; Liao M; Chen Y.-M; Kuo H.-P; Negoro S; Lam K.C; Armour A; Magill P; Fukuoka M. | Journal of Thoracic Oncology | 120 | 107 | |
2023 | HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy | Yu, Helena A; Goto, Yasushi; Hayashi, Hidetoshi; Felip, Enriqueta; CHIH-HSIN YANG ; Reck, Martin; Yoh, Kiyotaka; Lee, Se-Hoon; Paz-Ares, Luis; Besse, Benjamin; Bironzo, Paolo; Kim, Dong-Wan; Johnson, Melissa L; Wu, Yi-Long; John, Thomas; Kao, Steven; Kozuki, Toshiyuki; Massarelli, Erminia; Patel, Jyoti; Smit, Egbert; Reckamp, Karen L; Dong, Qian; Shrestha, Pomy; Fan, Pang-Dian; Patel, Parul; Sporchia, Andrea; Sternberg, David W; Sellami, Dalila; Jänne, Pasi A | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 10 | 5 | |
2023 | HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC | Yu, Helena A; CHIH-HSIN YANG ; Hayashi, Hidetoshi; Goto, Yasushi; Felip, Enriqueta; Reck, Martin; Vigliotti, Michele; Dong, Qian; Cantero, Frédérique; Fan, Pang-Dian; Kanai, Masayuki; Sternberg, David W; Jänne, Pasi A | Future oncology (London, England) | 5 | 2 | |
1999 | High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma | CHIH-HSIN YANG ; ANN-LII CHENG ; KUN-HUEI YEH ; CHONG-JEN YU ; Lin J.-F.; PAN-CHYR YANG | Cancer | 23 | | |
2008 | High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy | Perng R.-P.; CHIH-HSIN YANG ; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; CHONG-JEN YU ; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN ; Kao W.-Y. | Lung Cancer | 28 | 26 | |
2015 | High prevalence of the BIM deletion polymorphism in young female breast cancer in an East Asian country | CHING-HUNG LIN ; Shen C.-Y.; JIH-HSIANG LEE ; CHIUN-SHENG HUANG ; CHIH-HSIN YANG ; WEN-HUNG KUO ; DWANG-YING CHANG ; Hsiung C.-N.; KUAN-TING KUO ; WEI-WU CHEN ; I-CHUN CHEN ; Wu P.-F.; SUNG-HSIN KUO ; Chen C.-J.; YEN-SHEN LU ; ANN-LII CHENG | PLoS ONE | 10 | 6 | |
2015 | IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer | Liu Y.-N.; Chang T.-H.; Tsai M.-F.; SHANG-GIN WU ; TZU-HSIU TSAI ; Chen H.-Y.; SUNG-LIANG YU ; CHIH-HSIN YANG ; JIN-YUAN SHIH | Oncotarget | 57 | 56 | |
2013 | Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis | Lee C.K; Brown C; Gralla R.J; Hirsh V; Thongprasert S; Tsai C.-M; Tan E.H; Ho J.C.-M; Chu D.T; Zaatar A; Osorio Sanchez J.A; Vu V.V; Au J.S.K; Inoue A; Lee S.M; Gebski V; CHIH-HSIN YANG | Journal of the National Cancer Institute | 456 | 409 | |
2020 | The impact of smoking on the effectiveness of immune checkpoint inhibitors ??a systematic review and meta-analysis | Lee K.W.C; Lord S.J; Kasherman L; Marschner I; Stockler M; Gralla R; CHIH-HSIN YANG ; Mok T; Lee C.K. | Acta Oncologica | 13 | 12 | |
2015 | Impact of specific Epidermal Growth Factor Receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: A meta-analysis | Lee C.K; Wu Y.-L; Ding P.N; Lord S.J; Inoue A; Zhou C; Mitsudomi T; Rosell R; Pavlakis N; Links M; Gebski V; Gralla R.J; CHIH-HSIN YANG | Journal of Clinical Oncology | 277 | 244 | |
2021 | Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial | Park K.; ?zg?ro?lu, Mustafa; Vansteenkiste J.; Spigel D.; CHIH-HSIN YANG ; Bajars M.; Ruisi M.; Manitz J.; Barlesi F. | Lung Cancer | 1 | 1 | |
2019 | Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides | Hong S.-T; Lin H; Wang C.-S; Chang C.-H; Lin A.M.-Y; CHIH-HSIN YANG ; Lo Y.-L. | Journal of Nanobiotechnology | 35 | 32 | |
2018 | In reply | Gebski V; CHIH-HSIN YANG ; Lee C.K. | JAMA Oncology | 2 | 2 | |
2019 | Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients | ZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; CHIA-CHI LIN ; CHIH-HSIN YANG ; CHONG-JEN YU | European Journal of Cancer | 27 | 24 | |
2001 | Inflammation of seborrheic keratoses due to docetaxel treatment [11] | CHIA-YU CHU ; CHIH-HSIN YANG ; HSIEN-CHING CHIU | Acta Dermato-Venereologica | 10 | 7 | |
2010 | Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer | Wu J.-Y.; CHONG-JEN YU ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; PAN-CHYR YANG | Lung Cancer | 19 | 18 | |
2020 | The inhibition of Wnt restrain KRASG12V-driven metastasis in non-small-cell lung cancer | Hung P.-S.; Huang M.-H.; Kuo Y.-Y.; CHIH-HSIN YANG | Cancers | 8 | 6 | |